Unity Gross Profit from 2010 to 2025

UBX Stock

USD 2.11 0.32 17.88%

Unity Biotechnology Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit will likely drop to about -23.8 M in 2025. Gross Profit is the profit Unity Biotechnology makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2016-12-31

Previous Quarter

-221 K

Current Value

-216 K

Quarterly Volatility

9.8 M

Covid

Check Unity Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unity Biotechnology's main balance sheet or income statement drivers, such as Interest Income of 1.6 M, Depreciation And Amortization of 1.5 M or Interest Expense of 1.9 M, as well as many indicators such as Price To Sales Ratio of 104, Dividend Yield of 0.0 or PTB Ratio of 1.07. Unity financial statements analysis is a perfect complement when working with Unity Biotechnology Valuation or Volatility modules.

Check out the analysis of Unity Biotechnology Correlation against competitors.

For more information on how to buy Unity Stock please use our How to Invest in Unity Biotechnology guide.

Latest Unity Biotechnology's Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Unity Biotechnology over the last few years. Gross profit is a required income statement account that reflects total revenue of Unity Biotechnology minus its cost of goods sold. It is profit before Unity Biotechnology operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Unity Biotechnology's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unity Biotechnology's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (18.39 M)

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Unity Gross Profit Regression Statistics

	Arithmetic Mean	(14,110,337)
	Geometric Mean	9,207,963
	Coefficient Of Variation	(101.80)
	Mean Deviation	8,575,630
	Median	(13,707,000)
	Standard Deviation	14,364,146
	Sample Variance	206.3T
	Range	60.8M
	R-Value	(0.05)
	Mean Square Error	220.6T
	R-Squared	0
	Significance	0.87
	Slope	(138,437)
	Total Sum of Squares	3094.9T

Unity Gross Profit History

	2025	-23.8 M
	2024	-22.7 M
	2023	-19.7 M
	2022	-1.9 M
	2021	1.9 M
	2020	-3.4 M
	2019	-2.7 M

Other Fundumenentals of Unity Biotechnology

Gross Profit Margin

Unity Biotechnology Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Net Receivables	Long Term Debt Total	Net Invested Capital	Net Working Capital	Deferred Long Term Liab	Capital Stock	Current Deferred Revenue	Short Term Debt	Long Term Debt	Short Long Term Debt
Total Assets		0.69	0.55	0.28	-0.01	0.8	0.14	-0.3	0.89	0.6	0.46	-0.9	0.33	0.8	0.81	0.06	0.46	0.38	0.07	0.39	-0.44
Total Stockholder Equity	0.69		0.78	0.74	-0.51	0.89	0.59	-0.89	0.47	0.77	0.53	-0.71	0.55	0.33	0.41	0.49	0.05	0.25	0.31	-0.18	0.14
Net Tangible Assets	0.55	0.78		0.68	-0.7	0.73	0.81	-0.69	0.32	0.66	0.54	-0.66	0.68	0.11	0.22	0.69	-0.11	0.26	0.43	-0.42	0.38
Net Debt	0.28	0.74	0.68		-0.89	0.4	0.87	-0.82	-0.12	0.65	0.71	-0.51	0.68	-0.24	-0.21	0.8	-0.25	0.44	0.76	-0.64	0.55
Retained Earnings	-0.01	-0.51	-0.7	-0.89		-0.23	-0.98	0.69	0.35	-0.5	-0.6	0.33	-0.7	0.53	0.46	-0.91	0.42	-0.25	-0.81	0.86	-0.77
Accounts Payable	0.8	0.89	0.73	0.4	-0.23		0.36	-0.68	0.7	0.71	0.39	-0.71	0.49	0.53	0.63	0.27	0.26	0.13	-0.01	0.13	-0.14
Capital Surpluse	0.14	0.59	0.81	0.87	-0.98	0.36		-0.72	-0.2	0.59	0.62	-0.41	0.71	-0.42	-0.34	0.88	-0.34	0.24	0.76	-0.8	0.7
Total Liab	-0.3	-0.89	-0.69	-0.82	0.69	-0.68	-0.72		-0.07	-0.66	-0.44	0.39	-0.53	0.11	0.0	-0.6	0.22	-0.09	-0.39	0.49	-0.46
Total Current Assets	0.89	0.47	0.32	-0.12	0.35	0.7	-0.2	-0.07		0.3	0.03	-0.66	-0.07	0.91	0.95	-0.34	0.45	0.02	-0.25	0.59	-0.6
Common Stock	0.6	0.77	0.66	0.65	-0.5	0.71	0.59	-0.66	0.3		0.87	-0.68	0.67	0.16	0.2	0.55	0.5	0.41	0.26	-0.05	-0.11
Property Plant Equipment	0.46	0.53	0.54	0.71	-0.6	0.39	0.62	-0.44	0.03	0.87		-0.64	0.78	-0.02	-0.06	0.68	0.4	0.7	0.49	-0.16	0.0
Net Receivables	-0.9	-0.71	-0.66	-0.51	0.33	-0.71	-0.41	0.39	-0.66	-0.68	-0.64		-0.54	-0.57	-0.57	-0.4	-0.33	-0.38	-0.44	-0.07	0.19
Long Term Debt Total	0.33	0.55	0.68	0.68	-0.7	0.49	0.71	-0.53	-0.07	0.67	0.78	-0.54		-0.12	-0.13	0.88	0.04	0.58	0.47	-0.35	0.31
Net Invested Capital	0.8	0.33	0.11	-0.24	0.53	0.53	-0.42	0.11	0.91	0.16	-0.02	-0.57	-0.12		0.98	-0.4	0.53	0.12	-0.36	0.74	-0.71
Net Working Capital	0.81	0.41	0.22	-0.21	0.46	0.63	-0.34	0.0	0.95	0.2	-0.06	-0.57	-0.13	0.98		-0.37	0.46	0.02	-0.38	0.66	-0.63
Deferred Long Term Liab	0.06	0.49	0.69	0.8	-0.91	0.27	0.88	-0.6	-0.34	0.55	0.68	-0.4	0.88	-0.4	-0.37		-0.25	0.36	0.71	-0.72	0.64
Capital Stock	0.46	0.05	-0.11	-0.25	0.42	0.26	-0.34	0.22	0.45	0.5	0.4	-0.33	0.04	0.53	0.46	-0.25		0.23	-0.43	0.75	-0.87
Current Deferred Revenue	0.38	0.25	0.26	0.44	-0.25	0.13	0.24	-0.09	0.02	0.41	0.7	-0.38	0.58	0.12	0.02	0.36	0.23		0.21	0.1	-0.09
Short Term Debt	0.07	0.31	0.43	0.76	-0.81	-0.01	0.76	-0.39	-0.25	0.26	0.49	-0.44	0.47	-0.36	-0.38	0.71	-0.43	0.21		-0.75	0.62
Long Term Debt	0.39	-0.18	-0.42	-0.64	0.86	0.13	-0.8	0.49	0.59	-0.05	-0.16	-0.07	-0.35	0.74	0.66	-0.72	0.75	0.1	-0.75		-0.96
Short Long Term Debt	-0.44	0.14	0.38	0.55	-0.77	-0.14	0.7	-0.46	-0.6	-0.11	0.0	0.19	0.31	-0.71	-0.63	0.64	-0.87	-0.09	0.62	-0.96

Click cells to compare fundamentals

About Unity Biotechnology Financial Statements

Unity Biotechnology investors use historical fundamental indicators, such as Unity Biotechnology's Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unity Biotechnology. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	-22.7 M	-23.8 M
Gross Profit Margin	(7.41)	(7.78)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

MSFT	Microsoft
V	Visa Class A
C	Citigroup

Additional Tools for Unity Stock Analysis

When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC